References
- McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr. 2016;7:418–419.
- Menzies AM, Long GV. Systemic treatment for BRAF-mutant melanoma: where do we go next? Lancet Oncol. 2014;15:e371–e381.
- Farber E. Cell proliferation as a major risk factor for cancer: a concept of doubtful validity. Cancer Res. 1995;55:3759–3762.
- Quatresooz P, Pierard GE. Malignant melanoma: from cell kinetics to micrometastases. Am J Clin Dermatol. 2011;12:77–86.
- Pierard GE. Cell proliferation in cutaneous malignant melanoma: relationship with neoplastic progression. ISRN Dermatol. 2012;2012:828146.
- Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9:153–166.
- Sun L, Zhao R, Zhang L, et al. Prevention of vascular smooth muscle cell proliferation and injury-induced neointimal hyperplasia by CREB-mediated p21 induction: An insight from a plant polyphenol. Biochem Pharmacol. 2016;103:40–52.
- Waga S, Hannon GJ, Beach D, et al. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 1994;369:574–578.
- Diaz-Moralli S, Tarrado-Castellarnau M, Miranda A, et al. Targeting cell cycle regulation in cancer therapy. Pharmacol Ther. 2013;138:255–271.
- Peng L, Huang X, Jin X, et al. Wedelolactone, a plant coumarin, prevents vascular smooth muscle cell proliferation and injury-induced neointimal hyperplasia through Akt and AMPK signaling. Exp Gerontol. 2017;96:73–81.
- Xia Y, Chen J, Cao Y, et al. Wedelolactone exhibits anti-fibrotic effects on human hepatic stellate cell line LX-2. Eur J Pharmacol. 2013;714:105–111.
- Sarveswaran S, Gautam SC, Ghosh J. Wedelolactone, a medicinal plant-derived coumestan, induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCepsilon without inhibiting Akt. Int J Oncol. 2012;41:2191–2199.
- Liu YQ, Zhan LB, Liu T, et al. Inhibitory effect of Ecliptae herba extract and its component wedelolactone on pre-osteoclastic proliferation and differentiation. J Ethnopharmacol. 2014;157:206–211.
- Peng YG, Zhang L. Baohuoside-I suppresses cell proliferation and migration by up-regulating miR-144 in melanoma. Pharm Biol. 2018;56:43–50.
- Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002;14:381–395.
- Gwak H, Kim Y, An H, et al. Metformin induces degradation of cyclin D1 via AMPK/GSK3β axis in ovarian cancer. Mol Carcinog. 2017;56:349–358.
- Brownsey RW, Boone AN, Elliott JE, et al. Regulation of acetyl-CoA carboxylase. Biochem Soc Trans. 2006;34:223–227.
- Qi H, Liu Y, Li S, et al. Activation of AMPK attenuated cardiac fibrosis by inhibiting CDK2 via p21/p27 and miR-29 family pathways in rats. Mol Ther Nucleic Acids. 2017;8:277–290.
- Shen P, Yang X, Jiang J, et al. Wedelolactone from Eclipta alba inhibits lipopolysaccharide-enhanced cell proliferation of human renal mesangial cells via NF-kappaB signaling pathway. Am J Transl Res. 2017;9:2132–2142.
- Xu D, Lin TH, Yeh CR, et al. The wedelolactone derivative inhibits estrogen receptor-mediated breast, endometrial, and ovarian cancer cells growth. Biomed Res Int. 2014;2014:1.
- Ding H, Shi J, Wang Y, et al. Neferine inhibits cultured hepatic stellate cell activation and facilitates apoptosis: a possible molecular mechanism. Eur J Pharmacol. 2011;650:163–169.
- Hulit J, Wang C, Li Z, et al. Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol Cell Biol. 2004;24:7598–7611.
- Wang TC, Cardiff RD, Zukerberg L, et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature. 1994;369:669–671.
- Motoshima H, Goldstein BJ, Igata M, et al. AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol (Lond). 2006;574:63–71.
- Rattan R, Giri S, Singh AK, et al. 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem. 2005;280:39582–39593.